

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	03806.0590-00
-------	---	----	---	------------------------	---------------

PATENT TRADEMARK OFFICE  
U.S. DEPARTMENT OF COMMERCE  
Washington, DC 20590-0000  
www.uspto.gov

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
KH		4,353,905	10-12-1982	Sircar et al.	
		4,734,415	03-29-1988	Sircar et al.	
✓		5,418,233	05-23-1995	Linz et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
KH		EP 0 075 436 B1	03-30-1983	Warner-Lambert Company		English
		EP 1 061 077 A1	12-20-2000	Kowa Co., Ltd.		English
		EP 1 319 659 A1	6-18-2003	Eisai Co., Ltd.		English
		JP 9-216883	08-19-1997	Fujisawa Pharmaceutical Co. Ltd.		Yes
		WO 02/22587 A1	03-21-2002	Eisai Co., Ltd.		Abstract
		WO 02/50065 A2	06-27-2002	Vertex Pharmaceuticals Inc.		English
		WO 03/035065 A1	01-01-2003	Aventis Pharmaceuticals		English
✓		WO 03/059891 A1	07-24-2003	Pharmacia Corporation		English

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
KH		S. Nikouline et al., "Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle," <i>Diabetes</i> , Vo. 51, pp. 2190-2198, July 2002	
		E. Henriksen et al., "Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats," <i>Am. J. Physiol. Endocrinol. Metab.</i> , vol. 284, pp. 892-900, 2003	
		An English translation of JP 9-216883	
✓		An English language Patent Abstract of Japan of JP 9-216883	

Examiner Signature	<i>Mary H.</i>	Date Considered	3/20/2006
--------------------	----------------	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.